XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 1.19 | 1.46 | +22.69% | $377.3M | ✅ Beat | +3.30% | +6.23% | — |
| 2026-02-26 | Q4 2025 | 1.08 | 1.67 | +54.63% | $406.8M | ✅ Beat | -2.58% | +1.17% | -1.27% |
| 2025-11-06 |
| Q3 2025 |
| 1.18 |
| 1.27 |
| +7.63% |
| $384.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 1.58 | 1.57 | -0.63% | $378.0M | ❌ Miss | -0.85% | +3.70% | +5.55% |
| 2025-02-26 | Q4 2024 | 1.54 | 1.59 | +3.25% | $391.1M | ✅ Beat | -1.89% | +7.75% | +3.12% |
| 2024-11-06 | Q3 2024 | 1.56 | 1.70 | +8.97% | $378.7M | ✅ Beat | -3.13% | -12.52% | -2.36% |
| 2024-07-31 | Q2 2024 | 1.83 | 1.80 | -1.64% | $394.1M | ❌ Miss | -5.92% | -8.33% | +1.56% |
| 2024-05-02 | Q1 2024 | 1.54 | 1.69 | +9.74% | $370.0M | ✅ Beat | -3.39% | -2.92% | +6.23% |
Showing last 8 quarters.